Cargando…
The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
Atopic dermatitis (AD) is classified as a type 2 disease owing to the majority of type 2 lymphocytes that constitute the skin-infiltrating leukocytes. However, all of the type 1–3 lymphocytes intermingle in inflamed skin lesions. Here, using an AD mouse model where caspase-1 was specifically amplifi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960233/ https://www.ncbi.nlm.nih.gov/pubmed/36834723 http://dx.doi.org/10.3390/ijms24043310 |
_version_ | 1784895464267579392 |
---|---|
author | Yamanaka, Keiichi Kono, Yui Iida, Shohei Nakanishi, Takehisa Nishimura, Mai Matsushima, Yoshiaki Kondo, Makoto Habe, Koji Imai, Yasutomo |
author_facet | Yamanaka, Keiichi Kono, Yui Iida, Shohei Nakanishi, Takehisa Nishimura, Mai Matsushima, Yoshiaki Kondo, Makoto Habe, Koji Imai, Yasutomo |
author_sort | Yamanaka, Keiichi |
collection | PubMed |
description | Atopic dermatitis (AD) is classified as a type 2 disease owing to the majority of type 2 lymphocytes that constitute the skin-infiltrating leukocytes. However, all of the type 1–3 lymphocytes intermingle in inflamed skin lesions. Here, using an AD mouse model where caspase-1 was specifically amplified under keratin-14 induction, we analyzed the sequential changes in type 1–3 inflammatory cytokines in lymphocytes purified from the cervical lymph nodes. Cells were cultured and stained for CD4, CD8, and γδTCR, followed by intracellular cytokines. Cytokine production in innate lymphocyte cells (ILCs) and the protein expression of type 2 cytokine IL-17E (IL-25) were investigated. We observed that, as inflammation progresses, the cytokine-producing T cells increased and abundant IL-13 but low levels of IL-4 are produced in CD4-positive T cells and ILCs. TNF-α and IFN-γ levels increased continuously. The total number of T cells and ILCs peaked at 4 months and decreased in the chronic phase. In addition, IL-25 may be simultaneously produced by IL-17F-producing cells. IL-25-producing cells increased in a time-dependent manner during the chronic phase and may work specifically for the prolongation of type 2 inflammation. Altogether, these findings suggest that inhibition of IL-25 may be a potential target in the treatment of inflammation. |
format | Online Article Text |
id | pubmed-9960233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99602332023-02-26 The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis Yamanaka, Keiichi Kono, Yui Iida, Shohei Nakanishi, Takehisa Nishimura, Mai Matsushima, Yoshiaki Kondo, Makoto Habe, Koji Imai, Yasutomo Int J Mol Sci Article Atopic dermatitis (AD) is classified as a type 2 disease owing to the majority of type 2 lymphocytes that constitute the skin-infiltrating leukocytes. However, all of the type 1–3 lymphocytes intermingle in inflamed skin lesions. Here, using an AD mouse model where caspase-1 was specifically amplified under keratin-14 induction, we analyzed the sequential changes in type 1–3 inflammatory cytokines in lymphocytes purified from the cervical lymph nodes. Cells were cultured and stained for CD4, CD8, and γδTCR, followed by intracellular cytokines. Cytokine production in innate lymphocyte cells (ILCs) and the protein expression of type 2 cytokine IL-17E (IL-25) were investigated. We observed that, as inflammation progresses, the cytokine-producing T cells increased and abundant IL-13 but low levels of IL-4 are produced in CD4-positive T cells and ILCs. TNF-α and IFN-γ levels increased continuously. The total number of T cells and ILCs peaked at 4 months and decreased in the chronic phase. In addition, IL-25 may be simultaneously produced by IL-17F-producing cells. IL-25-producing cells increased in a time-dependent manner during the chronic phase and may work specifically for the prolongation of type 2 inflammation. Altogether, these findings suggest that inhibition of IL-25 may be a potential target in the treatment of inflammation. MDPI 2023-02-07 /pmc/articles/PMC9960233/ /pubmed/36834723 http://dx.doi.org/10.3390/ijms24043310 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamanaka, Keiichi Kono, Yui Iida, Shohei Nakanishi, Takehisa Nishimura, Mai Matsushima, Yoshiaki Kondo, Makoto Habe, Koji Imai, Yasutomo The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis |
title | The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis |
title_full | The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis |
title_fullStr | The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis |
title_full_unstemmed | The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis |
title_short | The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis |
title_sort | interplay of type 1, type 2, and type 3 lymphocytes and cytokines in atopic dermatitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960233/ https://www.ncbi.nlm.nih.gov/pubmed/36834723 http://dx.doi.org/10.3390/ijms24043310 |
work_keys_str_mv | AT yamanakakeiichi theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT konoyui theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT iidashohei theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT nakanishitakehisa theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT nishimuramai theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT matsushimayoshiaki theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT kondomakoto theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT habekoji theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT imaiyasutomo theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT yamanakakeiichi interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT konoyui interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT iidashohei interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT nakanishitakehisa interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT nishimuramai interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT matsushimayoshiaki interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT kondomakoto interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT habekoji interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis AT imaiyasutomo interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis |